Johnson & Johnson engages in the manufacture and sale of various products in the health care field worldwide.
There is no perfect dividend growth stock, but JNJ comes close. The company enjoys a diverse revenue base, an excellent research pipeline, a pristine balance sheet and exceptional free cash-flows to cover it dividend. This diversity and strength will help the company overcome near-term results from patent losses on Risperdal and Topamax. I will continue to add to my position as my allocation allows and when JNJ is trading below my buy price of $70.24.
Source: Dividends Value
Related Articles:
Dividend Growth Stocks News
- The pandemic preparedness dividend—investing today to prevent and mitigate tomorrow’s pandemics - Economist Impact - 7/24/2025
- 10 Overvalued Dividend Stocks To Sell - Sure Dividend - 7/24/2025
- 3 Undervalued Dividend Stocks Congress Members Are Buying - Investing.com - 7/24/2025
- 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - Yahoo Finance - 7/24/2025
- 3 Global Dividend Stocks With Up To 3.9% Yield - Yahoo Finance - 7/24/2025
- Chevron Corporation (CVX) Dividend Stock Analysis - 7/18/2025
- Emerson Electric Co. (EMR) Dividend Stock Analysis - 7/11/2025
- Amgen, Inc. (AMGN) Dividend Stock Analysis - 6/27/2025
- W.W. Grainger, Inc. (GWW) Dividend Stock Analysis - 6/20/2025
- Abbvie Inc. (ABBV) Dividend Stock Analysis - 6/13/2025
Stock Analysis: Johnson & Johnson (JNJ)
Posted by D4L | Thursday, May 27, 2010 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.